Childhood acute myeloid leukemia with bone marrow eosinophilia caused by t(16;21)(q24;q22)

被引：0
作者：
Nozomu Kawashima
Akira Shimada
Takeshi Taketani
Yasuhide Hayashi
Nao Yoshida
Kimikazu Matsumoto
Yoshiyuki Takahashi
Seiji Kojima
Koji Kato
机构：
[1] Japanese Red Cross Nagoya First Hospital,Division of Hematology/Oncology, Children’s Medical Center
[2] Nagoya University Graduate School of Medicine,Department of Pediatrics
[3] Shimane University Hospital,Division of Blood Transfusion
[4] Gunma Children’s Medical Center,Department of Hematology/Oncology
来源：
International Journal of Hematology | 2012年 / 95卷
关键词：
AML; Pediatric; Eosinophilia; t(16;21)(q24;q22); RUNX1-CBFA2T3;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Acute myeloid leukemia with abnormal bone marrow eosinophilia (AML-M4Eo) is often reported in core binding factor (CBF) leukemia, with translocations such as inv(16)(p13q22), t(16;16)(p13;q22) or t(8;21)(q22;q22); however, it is rarely reported with t(16;21)(q24;q22), which produces the RUNX1-CBFA2T3 (AML1-MTG16) chimera. The similarity between this chimera and RUNX1-RUNXT1 (AML1-MTG8) by t(8;21)(q22;q22) remains controversial. Adult leukemia with t(16;21)(q24;q22) was primarily therapy related, and shows poor prognosis; however, pediatric AML with this translocation was quite rare and tended to be de novo AML. We present here a 4-year-old boy with de novo AML-M4Eo and t(16;21)(q24;q22). He received chemotherapy and survived for more than 70 months without transplantation. We speculated that pediatric AML with t(16;21)(q24;q22) showed favorable prognosis, as with t(8;21)(q22;q22).
引用
收藏
页码：577 / 580
页数：3
相关论文
共 81 条
[1]  
Schnittger S(2007)Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients Leukemia 21 725-731
[2]  
Bacher U(1995)Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission Br J Haematol 91 104-108
[3]  
Haferlach C(2003)Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup Blood 102 462-469
[4]  
Kern W(2011)Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia Haematologica 96 1478-1487
[5]  
Haferlach T(1989)Cytogenetics of childhood acute nonlymphocytic leukemia Cancer Genet Cytogenet 40 13-27
[6]  
Tobal K(2002)A pediatric case of secondary leukemia associated with t(16;21)(q24;q22) exhibiting the chimeric AML1-MTG16 gene Leuk Lymphoma 43 415-420
[7]  
Johnson PR(2005)AML1-MTG16 gene rearrangement in a pediatric therapy related AML after Ewing sarcoma: a case discussion and review of literature Cancer Therapy. 3 285-292
[8]  
Saunders MJ(2010)Acute myeloid leukemia with t(16;21)(q24;q22) and eosinophilia: case report and review of the literature Cancer Genet Cytogenet 196 105-108
[9]  
Harrison CJ(2008)RUNX1-MTG16 fusion gene in acute myeloblastic leukemia with t(16;21)(q24;q22): case report and review of the literature Cancer Genet Cytogenet 185 47-50
[10]  
Liu Yin JA(2009)Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group J Clin Oncol 27 4007-4013
123456789